Dermatology Times Newsletter

To view this email as a web page, click here.

In our most recent Innovations column, Steve Xu, M.D., FAAD, discusses the new novel drugs that were approved in 2018, and provides his insight on how to collaborate with industry to foster innovation in dermatology. Read more from Dr. Xu here.

Novel dermatology drugs approved in 2018

In many ways, 2018 was a banner year for new novel drug approvals with 59 drugs approved by the FDA’s Center for Drug Evaluation and Research (CDER). Steve Xu, M.D., FAAD, highlights the approved dermatological drugs in this article.

Opportunities for collaboration with industry

How do you build industry relationships in dermatology? Steve Xu, M.D., and Michael L. Sierra, Ph.D., provide their insight on collaborating with industry in this article.

Don’t miss these psoriasis stories

New guidelines emphasize comorbidities in psoriasis

Is thyroid endocrinopathy associated with psoriasis?

From our Latest Issue

Energy-based device facial rejuvenation options

Targeted therapy for skin malignancies

Heart disease risk high in atopic eczema

JOB OPPORTUNITIES

CA - Contour Dermatology & Cosmetic Surgery Center

CA - Integrated Dermatology

CO - Integrated Dermatology

CO-Integrated Dermatology

CT - Integrated Dermatology

MA - Integrated Dermatology

District of Columbia-Integrated Dermatology

MA - Integrated Dermatology

MD - Integrated Dermatology

National - Integrated Dermatology

PA - Milton S Hershey Medical Center

NJ - Integrated Dermatology

NV - Integrated Dermatology

PA - Milton S Hershey Medical Center

PA - St. Luke's Physician Group

TN-Integrated Dermatology

VA - Integrated Dermatology

VT - Integrated Dermatology

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

CONNECT